WAVEMAN · COMPANY

PHAT · Phathom Pharmaceuticals, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

PHAT

Name: Phathom Pharmaceuticals, Inc. (PHAT) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Phathom Pharmaceuticals, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001783183

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+216.9%

XBRL, annual

NET MARGIN

-126.3%

CONVERSIONS · 180D

codes C/M, not in net · $86.6K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

81 funds added or opened last quarter

more than 58% of Pharma & Biotech

REVENUE

+216.9% year over year

more than 90% of Pharma & Biotech

MARGIN

-126.3% net margin

below 67% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

16.5% of shares outstanding short · 8.7 days to cover · settled 2026-07-31

more than 92% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

81 funds added or opened positions in the latest 13F quarter, of 164 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -23.6%

-23.6%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 81 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Phathom Pharmaceuticals, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Breedlove Robert Charles

Principal Accounting Officer

SELL

2025-11-03

524.0

$7.1K

Breedlove Robert Charles

Principal Accounting Officer

SELL

2025-09-05

461.0

$5.6K

Breedlove Robert Charles

Principal Accounting Officer

SELL

2025-07-16

1,692.0

$14.1K

Topper James N

Director

BUY

2025-05-21

3,780.0

$14.6K

Topper James N

Director

BUY

2025-05-14

6,300.0

$20.9K

64 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 59 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Frazier Life Sciences Management, L.P.

12,466,489.0 sh

$135.3M

Medicxi Ventures Management (Jersey) Ltd

7,464,572.0 sh

$81.0M

BlackRock, Inc.

4,525,129.0 sh

$49.1M

Invesco Ltd.

4,029,731.0 sh

$43.7M

Carlyle Group Inc.

3,496,808.0 sh

$37.9M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Simplify Propel Opportunities ETF

$2.9M POSITION · AS OF 2026-03-31

4.2%

Wasatch Micro Cap Fund

$9.0M POSITION · AS OF 2026-03-31

1.6%

State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF

$4.4M POSITION · AS OF 2026-03-31

1.4%

PROFUND VP PHARMACEUTICALS

$140.6K POSITION · AS OF 2026-03-31

1.4%

Wasatch Ultra Growth Fund

$5.5M POSITION · AS OF 2026-03-31

1.4%

Virtus Biotech Etf

$728.0K POSITION · AS OF 2026-04-30

1.2%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 12 registered trials, 3 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

0 ACTIVE

Phase 2

1 ACTIVE

Phase 3

1 ACTIVE

Not applicable

1 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2024

$3.6M

$3.8M

$1.5M

-28%

—

2023

$3.4M

$2.5M

$2.0M

-19%

—

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$175.1M	$55.3M	$682.0K	$0
GROSS PROFIT	$152.5M	$47.3M	$515.0K	$0
OPERATING INCOME	$-160.0M	$-277.5M	$-167.3M	$-172.4M
NET INCOME	$-221.2K	$-334.3K	$-201.6K	$-197.7M
EPS (DILUTED)	-3.03	-5.29	-3.93	-5.05
OPERATING CASH FLOW	$-166.8M	$-266.8M	$-137.6M	$-146.5M
CASH	$130.0M	$297.3M	$381.4M	$155.4M
LONG-TERM DEBT	$209.1M	$201.4M	$137.8M	$95.3M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE